Other substances

ARCoV

An RNA-based experimental COVID-19 vaccine.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Vaccine

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
2
 AI-suggested references
1
 Clinical trials

General information

ARCoV is an experimental lipid nanoparticle-encapsulated mRNA-based vaccine encoding receptor binding domain of the SARS-CoV-2 spike protein (Zhang et al., 2020).

ArRCov was approved for phase I clinical trials (ChiCTR2000034112) on June 19, 2020.

 

Supporting references

Link Tested on Impact factor Notes Publication date
A Thermostable mRNA Vaccine against COVID-19
Spike protein RNA Animal model 		Huh7 cells; BALB/c mice; Macaca fascicularis monkey 38.64

The lipid nanoparticle-encapsulated mRNA-based vaccine encoding receptor binding domain of the SARS-CoV-2 spike protein induced production of neutralizing antibodies and T cell immunity in mice and non-human primates. It protected immunized mice against mouse-adapted SARS-CoV-2 infection.

 Jul/23/2020

AI-suggested references

Link Publication date
Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial
Jan/07/2022
Long-term stability and protection efficacy of the RBD-targeting COVID-19 mRNA vaccine in nonhuman primates
Dec/24/2021

Clinical trials

ID Title Status Phase Start date Completion date
NCT04357808 Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID) Completed Phase 2 Apr/13/2020 Dec/04/2020
  • Alternative id - SARCOVID|2020-001634-36
  • Interventions - Drug: Sarilumab|Other: Standar of care
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Hospital Universitario de la Princesa, Madrid, Spain
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 30
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Mean change in clinical status assessment using the 7-point ordinal scale at day 7 after randomisation|Duration of hospitalisation (days)|Death|Time to become afebrile (days)|Time to non-invasive mechanical ventilation (days)|Time to invasive mechanical ventilation (days)|Time to independence from supplementary oxygen therapy (days)|Mean change in clinical status assessment using the 7-point ordinal scale at day 14 after randomisation
Export (.csv)